NeuralCIM® in Neurodegenerative Disorders: a hope to travel the path of Alzheimer’s.

Le résumé fourni par la source

Abstract Background NeuroEPO (NeuralCIM®) is a variant of EPO, which contains low sialic acid. NeuralCIM® is devoid of hematopoietic effects and produces clinical benefits in subjects with mild‐to‐moderate Alzheimer’s clinical syndrome. NeuralCIM® has received accelerated approval as a treatment for mild‐moderate AD, from the Cuban Regulatory Authority (CECMED). Method NeuralCIM® 0.5 mg was evaluated in patients who, after completing the clinical trial, continued to be treated with the drug, whether they had been included in the NeuralCIM® or placebo arm during trial. They were compared with subjects who did not request to continue treatment or who never received it, because they were included in the placebo group during the clinical study. Result After the clinical trial, the patients who continue to be treated with NeuralCIM® for two years from their inclusion in the clinical study, stabilized the disease. On the other hand, the subjects who did not continue the treatment with the drug, present a cognitive impairment characteristic of the progression of the disease. No serious adverse events related with NeuralCIM® were reported. Conclusion NeuralCIM® treatment, stabilized the progression of AD clinical syndrome, during two years of treatment.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.